Focus on respiratory diseases
Therapeutic applications of follistatin in the treatment of fibrosis and inflammation provide Paranta Biosciences with potentially huge market opportunities. The global inflammatory therapeutics market was estimated at US$57.8 billion in 2010 and is projected to increase to US$85.9 billion in 2017 (“Anti-Inflammatory Therapeutics Market to 2017 – Respiratory Diseases and Arthritis Continue to Dominate”, GBI Research, October 2011).
In the company’s focus area of respiratory diseases, it is estimated more than 300 million people are affected worldwide. In many lung diseases, pulmonary inflammation is a common and potentially serious association of the disease. Pulmonary inflammation often leads to the development of excess fibrotic material which impairs function of the lung with severe health consequences for the patient.
The 2010 market for asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, idiopathic pulmonary fibrosis (IPF), allergic rhinitis, cystic fibrosis (CF) and bronchitis was estimated at US$29.4 billion and is projected to increase to US$36.2 billion in 2017 (”Respiratory Disorders Therapeutics Market to 2017 – - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries”, GBI Research, September 2011). These estimates exclude treatments for acute viral pulmonary infections such as influenza, which are also indications of interest to Paranta Biosciences.